Deregulation of Toll-like receptor (TLR) mediated responses can have devastating effects on the host if left unchecked. It is, therefore, critical that control is exerted at several levels. In this review, we discuss post-translational modification of TLRs and their associated signaling molecules as one such means of control. In particular, we focus on the phosphorylation, ubiquitination and de-ubiquitination of various components of TLR signaling pathways.
Dunne A., O'Neill LAThe interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE2003, re3.
2.
Arbibe L., Mira JP, Teusch N. et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol2000 ; 1, 533—540.
3.
Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev1997; 11: 2295—2322.
4.
Marmiroli S. , Bavelloni A., Faenza I. et al. Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I. FEBS Lett1998; 438: 49—54.
5.
Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M.Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol2003; 33: 597—605.
6.
Sarkar SN, Smith HL, Rowe TM, Sen GCDouble-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J Biol Chem2003; 278: 4393—4396.
7.
Yamamoto M., Sato S., Mori K. et al. A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFNbeta promoter in the Toll-like receptor signaling. J Immunol2002; 169: 6668—6672.
8.
Sasai M., Oshiumi H., Matsumoto M. et al. NF-kappaB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation. J Immunol2005; 174: 27—30.
9.
Meylan E., Burns K., Hofmann K. et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol2004; 5: 503—507.
10.
Sarkar SN, Peters CP, Elco CP, Sakamato S., Pal S., Sen GCNovel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol2004; 11: 1060—1067.
11.
Naiki Y., Michelsen KS, Zhang W., Chen S., Doherty TM, Arditi M.TGF-beta differentially inhibits MyD88-dependent but not TRIF-dependent LPS-induced TLR4 signaling. J Biol Chem2005; 7: 5491—5495.
12.
O'Neill LA, Dunne A., Edjeback M., Gray P., Jefferies C., Weitek C.Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors. J Endotoxin Res2003; 9: 55—59.
13.
Cao Z., Henzel WJ, Gao X.IRAK: a kinase associated with the interleukin-1 receptor. Science1996; 271: 1128—1131.
14.
Li S., Strelow A., Fontana EJ, Wesche H.IRAK-4: a novel member of the IRAK family with the properties of an IRAKkinase . Proc Natl Acad Sci USA2002; 99: 5567—5572.
15.
Muzio M., Ni J., Feng P., Dixit VMIRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science1997; 278: 1612—1615.
16.
Wesche H., Gao X., Li X., Kirschning CJ, Stark GR, Cao Z.IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem1999; 274: 19403—19410.
17.
Kobayashi K. , Hernandez LD, Galan JE, Janeqay CA, Medzhitov R., Flavell RAIRAK-M is a negative regulator of Toll-like receptor signaling. Cell2002; 110: 191—202.
18.
Suzuki N., Suzuki S., Duncan GS et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature2002; 416: 750—756.
19.
Thomas JA, Allen JL, Tsen M. et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol1999; 163: 978—984.
20.
Burns K., Clatworthy J., Martin L. et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol2000; 2: 346—351.
21.
Kollewe C., Mackensen AC, Neumann D. et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling . J Biol Chem2004; 279: 5227—5236.
22.
Yamin TT, Miller DKThe interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem1997; 272: 21540—21547.
23.
Li X., Commane M., Burns C., Vithalani K., Cao Z., Stark GRMutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol1999; 19: 4643—4652.
24.
Qin J., Jiang Z., Qian Y., Casanova JL, Li X.IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem2004; 279: 26748—26753.
25.
Lye E., Mirtsos C., Suzuki N., Suzuki S., Yeh WCThe role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem2004; 279: 40653—40658.
26.
Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel DVTRAF6 is a signal transducer for interleukin-1. Nature1996; 383: 443—446.
27.
Kobayashi T. , Walsh PT, Walsh MC et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity2003; 19: 353—363.
28.
Kobayashi T. , Walsh MC, Choi Y.The role of TRAF6 in signal transduction and the immune response. Microbes Infect2004; 6: 1333—1338.
29.
Deng L., Wang C., Spenser E. et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain . Cell2000; 103: 351—361.
Chau V., Tobias JW, Bachmair A. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science1989; 243: 1576—1583.
32.
Hofmann RM, Pickart CMNoncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell1999; 96: 645—653.
33.
Ea CK, Sun L., Inoue J., Chen ZJTIFA activates IkappaB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6. Proc Natl Acad Sci USA2004; 101: 15318—15323.
34.
Sun L., Deng L., Ea CK, Xia ZP, Chen ZJThe TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell2004; 14: 289—301.
35.
Rothe M., Wong SC, Henzel WJ, Goeddel DVA novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell1994; 78: 681—692.
36.
Yang K., Zhu J., Sun S. et al. The coiled-coil domain of TRAF6 is essential for its auto-ubiquitination . Biochem Biophys Res Commun2004; 324: 432—439.
37.
Wang C., Deng L., Hong M., Akkaraju GR, Inoue J., Chen ZJTAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature2001; 412: 346—351.
38.
Kanayama A. , Seth RB, Sun L. et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell2004; 15: 535—548.
39.
Amerik AY, Hochstrasser M.Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta2004; 1695: 189—207.
40.
Jensen LE, Whitehead ASUbiquitin activated tumor necrosis factor receptor associated factor-6 (TRAF6) is recycled via deubiquitination. FEBS Lett2003; 553: 190—194.
41.
Boone DL, Turer EE, Lee EG et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol2004; 5: 1052—1060.
42.
Beyaert R., Heyninck K., Van Huffel S.A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol2000: 60: 1143—1151.
43.
Donze O., Deng J., Curran J., Sladek R., Picard D., Sonenberg N.The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J2004; 23: 564—571.
44.
Saitoh T., Yamamoto M., Miyagishi M. et al. A20 is a negative regulator of IFN regulatory factor 3 signaling . J Immunol2005; 174: 1507—1512.
45.
Wertz IE, O'Rourke KM, Zhou H. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature2004; 430: 694—699.
Shimura H., Schlossmacher MG, Hattori N. et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science2001; 293: 263—269.
48.
Niwa J., Ishigaki S., Hishikawa N. et al. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem2002; 277: 36793—36798.
49.
Treier M., Staszewski LM, Bohmann D.Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain . Cell1994; 78: 787—798.
50.
Hustad CM, Perry WL, Siracusa LD et al. Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. Genetics1995; 140: 255—265.
51.
Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NGThe itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet1998; 18: 143—146.
52.
Lu Z., Xu S., Joazeiro C., Cobb MH, Hunter T.The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell2002; 9: 945—956.
53.
Abbott DW, Wilkins A., Asara JM, Cantley LCThe Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol2004; 14: 2217—2227.
54.
Kawai T., Sato S., Ishii KJ et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol2004; 5: 1061—1068.
55.
Takaoka A., Yanai H., Kondo S. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature2005; 434: 243—249.
56.
Brint EK, Xu D., Liu H. et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol2004; 5: 373—379.
57.
Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med2003; 197: 263—268.
